The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ababneh, Obada, Abushukair, Hassan, Qarqash, Aref, Syaj, Sebawe, Al Hadidi, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358782/
https://www.ncbi.nlm.nih.gov/pubmed/35950210
http://dx.doi.org/10.1007/s44228-022-00007-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358782/
https://www.ncbi.nlm.nih.gov/pubmed/35950210
http://dx.doi.org/10.1007/s44228-022-00007-5

Ejemplares similares